Browse Articles
Discover research articles across all indexed journals
Inhibiting Overoxidation of Dynamically Evolved RuO<sub>2</sub> to Achieve a Win–Win in Activity–Stability for Acidic Water Electrolysis
Bremsstrahlung radiation from toroidal plasmas generated through hydrodynamic shear
Wearable-derived short sleep duration is associated with higher C-reactive protein in a placebo-controlled vaccine trial among young adults
Steel surface defect detection based on multi-layer fusion networks
PKD1 mutation perturbs morphogenesis in tubular epithelial organoids derived from human pluripotent stem cells
RORα fine-tunes the circadian control of hepatic triglyceride synthesis and gluconeogenesis
Reaction wetting and interfacial properties calculation of NiFe binary alloy droplets on Fe substrate
Author Correction: Predicting mortality after transcatheter aortic valve replacement using preprocedural CT
New lasso-shaped antibiotic kills drug-resistant bacteria
Combining laser biomimetic surface microtextured and PTFE solid lubricant for improved friction property of Ti6Al4V
Ecological evaluation of dominant roadside plants through APTI and API for sustainable green belt development in cosmopolitan city (Lahore) of Pakistan
A map of mitochondrial biology reveals the energy landscape of the human brain
The Astrocytic Zinc Transporter ZIP12 Is a Synaptic Protein That Contributes to Synaptic Zinc Levels in the Mouse Auditory Cortex
Synaptically released zinc is a neuronal signaling system that arises from the actions of the presynaptic vesicular zinc transporter protein zinc transporter 3 (ZnT3). Mechanisms that regulate the actions of zinc at synapses are of great importance for many aspects of synaptic signaling in the brain. Here, we identify the astrocytic zinc transporter protein ZIP12 as a candidate mechanism that contributes to zinc clearance at cortical synapses. We identify small-molecule compounds that antagonize the function of ZIP12 in heterologous expression systems, and we use one of these compounds, ZIP12 modulator 8, to increase the concentration of ZnT3-dependent zinc at synapses in the brain of male and female mice to inhibit the activity of neuronal AMPA and NMDA glutamate receptors. These results identify a cellular mechanism and provide a pharmacological toolbox to target the molecular machinery that supports the actions of synaptic zinc in the brain.
Multi-omics integration identifies molecular markers and biological pathways for carcass and meat quality traits in Nellore cattle
Deep neural networks excel in COVID-19 disease severity prediction—a meta-regression analysis
Abstract COVID-19 is a disease in which early prognosis of severity is critical for desired patient outcomes and for the management of limited resources like intensive care unit beds and ventilation equipment. Many prognostic statistical tools have been developed for the prediction of disease severity, but it is still unclear which ones should be used in practice. We aim to guide clinicians in choosing the best available tools to make optimal decisions and assess their role in resource management and assess what can be learned from the COVID-19 scenario for development of prediction models in similar medical applications. Using the five major medical databases: MEDLINE (via PubMed), Embase, Cochrane Library (CENTRAL), Cochrane COVID-19 Study Register, and Scopus, we conducted a comprehensive systematic review of prediction tools between 2020 January and 2023 April for hospitalized COVID-19 patients. We identified both the relevant confounding factors of tool performance using the MetaForest algorithm and the best tools—comparing linear, machine learning, and deep learning methods—with mixed-effects meta-regression models. The risk of bias was evaluated using the PROBAST tool. Our systematic search identified eligible 27,312 studies, out of which 290 were eligible for data extraction, reporting on 430 independent evaluations of severity prediction tools with ~ 2.8 million patients. Neural Network-based tools have the highest performance with a pooled AUC of 0.893 (0.748–1.000), 0.752 (0.614–0.853) sensitivity, 0.914 (0.849–0.952) specificity, using clinical, laboratory, and imaging data. The relevant confounders of performance are the geographic region of patients, the rate of severe cases, and the use of C-Reactive Protein as input data. 88% of studies have a high risk of bias, mostly because of deficiencies in the data analysis. All investigated tools in use aid decision-making for COVID-19 severity prediction, but Machine Learning tools, specifically Neural Networks clearly outperform other methods, especially in cases when the basic characteristics of severe and non-severe patient groups are similar, and without the need for more data. When highly specific biomarkers are not available—such as in the case of COVID-19—practitioners should abandon general clinical severity scores and turn to disease specific Machine Learning tools.